“0.5 mg, yellow, round, biconvex, coated tablets debossed with "1" on one side and plain on other side”
1 pill
Pill with imprint 1 is yellow, round, 5 mm and has been identified as Sirolimus 0.5 mg. It is used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms. It is supplied by Zydus Pharmaceuticals USA Inc.
Sirolimus 0.5 mg
- Imprint
- 1
- Strength
- 0.5 mg
- Used for
- Lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- Color
- Yellow
- Shape
- Round
- Size
- 5 mm
- Score
- No score line
- Form
- Tablet, film coated
- Manufacturer
- Zydus Pharmaceuticals USA Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- NDC
- 68382-520, 68382-520-30, 68382-520-77, 68382-520-01, 68382-520-06, 68382-520-16, 68382-520-05, 68382-520-10, 65841-771, 65841-771-01, 65841-771-06, 65841-771-16, 65841-771-05, 65841-771-10, 65841-771-30, 65841-771-77, 70518-4376, 70518-4376-1, 70518-4376-0, 60687-902, 60687-902-11, 60687-902-21
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Sirolimus used for?
Sirolimus is used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms.
- Medicine type
- Cancer medicine (kinase inhibitor); immune suppressant
Official uses from the US prescribing label
Prophylaxis of Organ Rejection in Renal Transplantation
Sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.
In patients at low-to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation.
In patients at high-immunologic risk(defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation.
Limitations of Use in Renal Transplantation
Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, those with serum creatinine >4.5 mg/dL, Black patients, patients of multi-organ transplants, secondary transplants, or those with high levels of panel-reactive antibodies.
In patients at high-immunologic risk, the safety and efficacy of sirolimus tablets used in combination with cyclosporine and corticosteroids has not been studied beyond one year; therefore after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient.
In pediatric patients, the safety and efficacy of sirolimus tablets have not been established in patients <13 years old, or in pediatric (<18 years) renal transplant patients considered at high-immunologic risk.
The safety and efficacy of de novouse of sirolimus tablets without cyclosporine have not been established in renal transplant patients.
The safety and efficacy of conversion from calcineurin inhibitors to sirolimus tabletsin maintenance renal transplant patients have not been established.
Treatment of Patients with Lymphangioleiomyomatosis
Sirolimus tablets are indicated for the treatment of patients with lymphangioleiomyomatosis (LAM).
From the FDA-approved label on DailyMed (published Sep 14, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows 1 and the other side is plain.
- It is yellow, round, 5 mm.
- The score line, coating and any logo match the photo.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Sirolimus
Inactive: .alpha.-Tocopherol Acetate, Cellulose, Microcrystalline, Citric Acid Monohydrate, Crospovidone, Fd&c Yellow No. 5, Ferric Oxide Yellow, Glyceryl Monooleate, Hypromellose, Unspecified, Lactose Monohydrate, Poloxamer 188, Polyethylene Glycol, Unspecified, Povidone, Sucrose, Talc, Titanium Dioxide
Also distributed by
Zydus Lifesciences Limited, Remedyrepack Inc., American Health Packaging
Other pills with imprint 1
Same imprint, different listing. Check the color, size and maker against your pill.
-
1
Amitriptyline Hydrochloride 10 mg
Pink, round, 5 mm
Used for depression and pain
- 1 Atorvastatin Calcium 10 mg White, round, 5 mm Used for high cholesterol and high triglycerides
- 1 Benzonatate 100 mg Yellow, oval, 8 mm Used for cough and hiccup
- 1 Benzonatate 100 mg Yellow, round, 7 mm Used for cough and hiccup
- 1 Clonazepam 1 mg Green, round, 8 mm Used for panic disorder and bipolar disorder Schedule IV
- 1 Everolimus 2.5 mg White, capsule Used for seizures
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
AN 247
Chlorthalidone 25 mg
Yellow, round, 6 mm
Used for high blood pressure and heart failure
-
AN899 15
Aripiprazole 15 mg
Yellow, round, 6 mm
Used for schizophrenia
-
C
Olmesartan Medoxomil 5 mg
Yellow, round, 5 mm
Used for high blood pressure and heart failure
-
G 51
Solifenacin Succinate 5 mg
Yellow, round, 6 mm
Used for overactive bladder
-
C C 54
Clozapine 25 mg
Yellow, round, 6 mm
Used for bipolar disorder and schizophrenia
-
121 YL
Letrozole Tablets 2.5 mg
Yellow, round, 6 mm
Other Sirolimus pills
-
RD53
Sirolimus 1 mg
White, triangle, 5 mm
Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
-
Y 77
Sirolimus 1 mg
White, round, 6 mm
Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- S Sirolimus 0.5 mg Brown, round, 4 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- RAPAMUNE 05 MG Sirolimus 0.5 mg Brown, triangle, 8 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- Y 7 Sirolimus 0.5 mg Gray, round, 4 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- 11 Sirolimus 1 mg White, round, 7 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- S 1 Sirolimus 1 mg White, round, 6 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms
- RAPAMUNE 1 MG Sirolimus 1 mg White, triangle, 8 mm Used for lymphangioleiomyomatosis and perivascular epithelioid cell neoplasms